Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 41, Issue 3, 2016, Pages 152-161

  Kirschner, Matthias ^a   Hager, Oliver M ^a,b   Bischof, Martin ^a   Hartmann, Matthias N ^a,b   Kluge, Agne ^a   Seifritz, Erich ^a   Tobler, Philippe N ^b   Kaiser, Stefan ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT; OXYGEN;

ADULT; ANTICIPATION; APATHY; ARTICLE; CLINICAL ARTICLE; COGNITIVE FUNCTION TEST; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYPOACTIVITY; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; NEUROPSYCHOLOGICAL TEST; POSITIVE SYNDROME; SCHIZOPHRENIA; VENTRAL STRIATUM; BLOOD; BRAIN CIRCULATION; BRAIN MAPPING; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; REWARD;

ADULT; ANTIPSYCHOTIC AGENTS; APATHY; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; OXYGEN; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VENTRAL STRIATUM;

EID: 84964762239     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140383     Document Type: Article

References (59)

1. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-9.
2. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32:238-45.
3. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506.
4. Strauss GP, Harrow M, Grossman LS, et al. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull 2010;36:788-99.
5. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 2013;47:783-90.
6. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 2010;36:359-69.
7. Messinger JW, Tremeau F, Antonius D, et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 2011; 31:161-8.
8. Liemburg E, Castelein S, Stewart R, et al. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res 2013;47:718-25.
9. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-62.
10. Brown RG, Pluck G. Negative symptoms: the "pathology" of motivation and goal-directed behaviour. Trends Neurosci 2000;23:412-7.
11. Gold JM, Strauss GP, Waltz JA, et al. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry 2013;74:130-6.
12. Hartmann MN, Hager OM, Reimann AV, et al. Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr Bull 2015;41: 503-12.
13. Barch DM, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 2010;36:919-34.
14. Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 2014;40:S107-16.
15. Knutson B, Westdorp A, Kaiser E, et al. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage 2000;12:20-7.
16. Knutson B, Gibbs SEB. Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology (Berl) 2007;191:813-22.
17. Berridge KC, Robinson TE. Parsing reward. Trends Neurosci 2003; 26: 507-13.
18. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006;187:222-8.
19. Nielsen MØ, Rostrup E, Wulff S, et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry 2012;71:898-905.
20. Morris RW, Vercammen A, Lenroot R, et al. Disambiguating ventral striatum fMRI-related bold signal during reward prediction in schizophrenia. Mol Psychiatry 2012;17:235-9.
21. De Leeuw M, Kahn RS, Vink M. Fronto-striatal dysfunction during reward processing in unaffected siblings of schizophrenia patients. Schizophr Bull 2015;41:94-103.
22. Grimm O, Heinz A, Walter H, et al. Striatal response to reward anticipation: evidence for a systems-level intermediate phenotype for schizophrenia. JAMA Psychiatry 2014;71:531-9.
23. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006; 29:409-16.
24. Schlagenhauf F, Juckel G, Koslowski M, et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008;196:673-84.
25. Waltz JA, Schweitzer JB, Gold JM, et al. Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology 2009; 34:1567-77.
26. Wolf DH, Turetsky BI, Loughead J, et al. Auditory oddball fMRI in schizophrenia: association of negative symptoms with regional hypoactivation to novel distractors. Brain Imaging Behav 2008;2:132-45.
27. Dowd EC, Barch DM. Anhedonia and emotional experience in schizophrenia: neural and behavioral indicators. Biol Psychiatry 2010;67:902-11.
28. Simon JJ, Biller A, Walther S, et al. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr Res 2010;118:154-61.
29. Waltz JA, Schweitzer JB, Ross TJ, et al. Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 2010;35:2427-39.
30. Wolf DH, Satterthwaite TD, Kantrowitz JJ, et al. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull 2014;40:1328-37.
31. Ehrlich S, Yendiki A, Greve DN, et al. Striatal function in relation to negative symptoms in schizophrenia. Psychol Med 2012;42:267-82.
32. Mucci A, Dima D, Soricelli A, et al. Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol Med 2015;45:1765-78.
33. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010;67:231-9.
34. Salamone JD, Koychev I, Correa M, et al. Neurobiological basis of motivational deficits in psychopathology. Eur Neuropsychopharmacol 2015;25:1225-38
35. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull 2011;37: 300-5.
36. Lecrubier Y, Weiller E, Herugeta T, et al. Mini International Neuropsychiatric Interview German Version 5.0.0. München: Psychiatrischen Universitätsklinik München; 1999.
37. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;7:59-67.
38. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
39. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982;39:784-8.
40. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
41. Frances A, Pincus HA, First MB. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
42. Juckel G, Schaub D, Fuchs N, et al. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res 2008;104:287-93.
43. Cools R, Blackwell A, Clark L, et al. Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity. Neuropsychopharmacology 2005;30:1362-73.
44. Van Dijk KRA, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional connectivity MRI. Neuroimage 2012;59:431-8.
45. Satterthwaite TD, Wolf DH, Loughead J, et al. Impact of in-scanner head motion on multiple measures of functional connectivity: relevance for studies of neurodevelopment in youth. Neuroimage 2012;60:623-32.
46. Knutson B, Greer SM. Anticipatory affect: neural correlates and consequences for choice. Philos Trans R Soc Lond B Biol Sci 2008;363: 3771-86.
47. Yip SW, Worhunsky PD, Rogers RD, et al. Hypoactivation of the ventral and dorsal striatum during reward and loss anticipation in antipsychotic and mood stabilizer-naive bipolar disorder. Neuropsychopharmacology 2015;40:658-66.
48. Alemán-Gómez Y, Melie-García L. Valdés-Hernandez P. IBASPM: Toolbox for automatic parcellation of brain structures. Presented at the 12th Annual Meeting of the Organization for Human Brain Mapping, June 11-15, 2006, Florence, Italy.
49. Maldjian JA, Laurienti PJ, Kraft RA, et al. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003;19:1233-9.
50. Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull 1980;87:245-51.
51. Fervaha G, Graff-Guerrero A, Zakzanis KK, et al. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. J Psychiatr Res 2013;47:1590-6.
52. Peralta V, Cuesta MJ, Martinez-Larrea A, et al. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 2000;157:1461-6.
53. Kirkpatrick B. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression. J Clin Psychiatry 2014;75(Suppl 1):3-7.
54. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-88.
55. Salamone JD, Correa M, Nunes EJ, et al. The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav 2012;97:125-46.
56. Peciña S, Cagniard B, Berridge KC, et al. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 2003;23:9395-402.
57. Wyvell CL, Berridge KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward "wanting" without enhanced "liking" or response reinforcement. J Neurosci 2000;20:8122-30.
58. Kring AM, Barch DM. The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur Neuropsychopharmacol 2014;24:725-36.
59. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria Project. Schizophr Bull 2010;36:1061-2.